# A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

> **NCT06938321** · PHASE1,PHASE2 · RECRUITING · sponsor: **Akeso** · enrollment: 135 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** AK112
- **DRUG:** AK130

## Key facts

- **NCT ID:** NCT06938321
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2027-05
- **Final completion:** 2027-12
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06938321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06938321, "A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-09-20 from https://api.ai-analytics.org/clinical/NCT06938321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*